108498-50-6
|
|
- CAS号:
- 108498-50-6
- 英文名:
- FRG 8701
- 英文别名:
- FRG 8701;FRG8701,FRG-8701;Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-
- 中文名:
- 108498-50-6
- 中文别名:
- 化合物 T11324
- CBNumber:
- CB31376213
- 分子式:
- C22H30N2O4S
- 分子量:
- 418.55
- MOL File:
- 108498-50-6.mol
|
|
|
108498-50-6化学性质
-
沸点:
-
675.2±55.0 °C(Predicted)
-
|
-
密度:
-
1.226±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
-
酸度系数(pKa):
-
13.77±0.46(Predicted)
-
|
108498-50-6性质、用途与生产工艺
FRG-8701 是一种新组氨酸 H2-receptor 拮抗剂,IC50 值为 0.25 至 0.43 μM。
IC50: 0.25 to 0.43 μM (Histamine H
2
-receptor)
Positive chronotropic response to histamine at 10
-5
M is dose dependently inhibited by FRG8701 (FRG-8701) famotidine or cimetidine; and the IC
50
values of FRG8701, famotidine and cimetidine are 3.3, 3.0 and 108.6 (×10
-7
M), respectively.The inhibitory potency of FRG8701 is almost the same as that of famotidine and approximately 33 times greater than that of cimetidine.
In the pylorus-ligated (4 hr) rats, each drug, given intraduodenally, dose-dependently inhibits the total acid output. FRG8701 at 10 or 30 mg/kg, given orally or intraperitoneally, significantly prevent the formation of the gastric mucosal lesions induced by 0.4 N HCI+50% ethanol (HCI•ethanol). Other necrotizing agents-induced gastric lesions are also inhibited by treatment of
FRG8701. The oral ED
50
values against the lesions range from 1.1 to 9.4 mg/kg. FRG8701, given orally, dose-dependently prevents the development of gastric lesions induced by stress and indomethacin. Duodenal ulcer induced by mepirizole is also inhibited with FRG8701. The ED
50
values of FRG8701 for each ulcer model range from 1.7 to 6.9 mg/kg.
108498-50-6
上下游产品信息
上游原料
下游产品
108498-50-6, 108498-50-6 相关搜索:
- 化合物 T11324
- 108498-50-6
- FRG8701,FRG-8701
- Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-
- FRG 8701